Trials / Unknown
UnknownNCT03631563
ATG-F VS ATG for the Prevention of GVHD
Comparing ATG-Fresenius vs Thymoglobulin for the Prevention of Graft-versus-host Disease in the Setting of Haplo-identical Hematopoietic Stem Cell Transplantation
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- —
Summary
Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.The study aims to compare the efficacy and safety of ATG-F vs ATG, incorporated into the preparative regimens for haplo-identical transplants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Immunosuppressive Agent | ATG-Fresenius versus ATG |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2018-12-01
- Completion
- 2020-12-01
- First posted
- 2018-08-15
- Last updated
- 2018-08-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03631563. Inclusion in this directory is not an endorsement.